# FORTITUDE-101 (NCT05052801)

> Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05052801
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
- Interventions: Bemarituzumab; mFOLFOX6; Placebo
- Enrollment: 547
- Primary outcome: Overall Survival

## Commentary we found

- X threads: 26
- YouTube: 13
- Podcasts: 11
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=fortitude-101-nct05052801

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05052801", "email": "<work email>"}; the inbox owner confirms by the emailed link.